EconomyUnited StatesHighScore 7.0

Regeneron reaches deal with Trump administration to lower drug prices and avoid planned tariffs. CEO Leonard Schleifer says the company aims to balance industry support with drug affordability.

Regeneron has reached an agreement with the Trump administration to reduce drug prices in exchange for avoiding planned tariffs. CEO Leonard Schleifer stated the company aims to support the industry while ensuring drug affordability.

What happened

Regeneron has reached an agreement with the Trump administration to reduce drug prices in exchange for avoiding planned tariffs. CEO Leonard Schleifer stated the company aims to support the industry while ensuring drug affordability.

Quick reaction

One tap helps tune what we surface next.

Reader discussion

Public comments
0/1000

No comments yet. Start the discussion around this signal.

Follow this signal

Get updates on this story

We will email you if this changes materially. No spam. Daily brief optional.

Map context

Open map near United States

Keep the story in context with nearby live signals, countries, and category movement.

Open live map

Related coverage

More live signals

Continue with the live feed.

The fastest nearby updates load from the public feed, not the enriched story endpoint.

Continue with live feed

Monitor

Track follow-ups in Monitor

Turn this public story into a watchlist seed for matching future signals, team alerts, and operational routing.

Signals API

Use these signals via API

Evaluate structured event payloads, canonical URLs, categories, geo fields, and confidence metadata for your own workflows.